BioCryst Pharmaceuticals (BCRX) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCRX shares.
View BCRX analyst ratings or view top-rated stocks.

7 analysts have issued twelve-month price targets for BioCryst Pharmaceuticals' stock. Their BCRX share price forecasts range from $10.00 to $30.00. On average, they anticipate the company's share price to reach $13.63 in the next twelve months. This suggests a possible upside of 112.2% from the stock's current price.
View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts.

BioCryst Pharmaceuticals' stock was trading at $11.48 on January 1st, 2023. Since then, BCRX shares have decreased by 44.1% and is now trading at $6.42.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our BCRX earnings forecast.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. The biotechnology company had revenue of $81.01 million for the quarter, compared to the consensus estimate of $81.42 million. BioCryst Pharmaceuticals's quarterly revenue was up 24.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.32) EPS.

ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ETFMG Treatments Testing and Advancements ETF (GERM) and Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO).

9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCRX stock can currently be purchased for approximately $6.42.

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a market capitalization of $1.22 billion and generates $270.83 million in revenue each year. The biotechnology company earns $-247,120,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

The company employs 531 workers across the globe.

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The official website for the company is www.biocryst.com. The biotechnology company can be reached via phone at (919) 859-1302, via email at investorrelations@biocryst.com, or via fax at 919-859-1314.